New EMA Guidance Qualification of novel Methodologies for Drug Development
Recommendation
28/29 April 2026
From QbD to Process Validation
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The European Medicines Agency EMA has published the revised Guidance to Applicants "Qualification of novel methodologies for drug development" (EMA/CHMP/SAWP/72894/2008). This guidance has already been finally agreed by CHMP in early 2009 and has now been revised for the second time. What's new is mainly the inclusion of the dates and deadlines for submission of letters of intent for qualification of novel methodologies.
The qualification process described in the document addresses innovative drug development methods and tools in pharmaceuticals R&D and compromises the whole procedure:
- Intention to submit a request
- Appointment of the Coordinator and the Qualification team on behalf of the CHMP (Committee for Medicinal Products for Human Use)
- Preparatory meeting
- Evaluation of data and discussion with the applicants
- SAWP (Scientific Advice Working Party) review
- CHMP adoption of Qualification Advice and discussion of Qualification Opinion
- Public consultation (for Qualification Opinion only)
- Adoption of the final CHMP Qualification Opinion
Related GMP News
11.12.2025Insurance Review in Phase 1 Clinical Trials
11.12.2025EMA Publishes Comments on ICH E21
27.11.2025Final ICH M14 Guideline on the Use of RWD for Safety Assessment
25.11.2025Clinical Trials: BMG publishes Standard Contractual Clauses Ordinance
04.11.2025UK Clinical Trials Regulations: Six-Month Countdown
04.11.2025Clinical Trials - Update on the CTIS